During the past decade, Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 11 clinical trials were completed, i.e. on average, 64.7% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 7 clinical trials were completed. i.e. 87.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii" #1 sponsor was "Incyte Corporation" with 10 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Pfizer" with 2 trials sponsored, "University of Heidelberg Medical Center" with 2 trials sponsored and "Incyte Biosciences International Sàrl" with 2 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Foundation Medicine, Inc." with 1 trials as a collaborator, "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator and "Institute of Cancer Research, United Kingdom" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii" are "Multiple Myeloma" (4 trials), "Lymphoma" (3 trials), "Follicular Lymphoma" (2 trials), "Non-Hodgkin's Lymphoma" (2 trials) and "Cancer of Unknown Primary Site" (1 trials). Many other conditions were trialed in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii" in a lesser frequency.

Most popular intervention types in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii" are "Drug" (20 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bortezomib" (3 trials), "Dexamethasone" (3 trials), "Parsaclisib" (3 trials), "Placebo" (3 trials) and "Atezolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii" are 20 trials for "All" genders.

Currently, there are NaN active trials in "Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii". undefined are not yet recruiting, 3 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii, 3 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".